Search Results

You are looking at 21 - 30 of 403 items for :

  • "bevacizumab" x
  • Refine by Access: All x
Clear All
Full access

Sequencing of Treatment in Advanced Unresectable Colorectal Cancer

Jean L. Grem

also be used for palliation in the setting of obstruction or bleeding. A concern has been the risk of perforation of the primary tumor with the use of bevacizumab-containing therapy. National Surgical Adjuvant Breast and Bowel Project (NSABP) protocol

Full access

New Therapies for Ovarian Cancer

David M. O’Malley

and bevacizumab have made a profound difference in progression-free survival (PFS) for patients with ovarian cancer. All patients should have genetic testing and be treated accordingly. The potential for cure is on the horizon,” he added. Dr. O

Full access

Avastin, ODAC, and the FDA: Are We Drafting the Right Players?

Harold J. Burstein

provide confirmatory evidence supporting the original ECOG 2100 study that had led to accelerated approval of bevacizumab in combination with paclitaxel for advanced breast cancer. The FDA will decide in September whether to withdraw the label for the

Full access

Counterpoint: Adjuvant Therapy in Stage II Colon Cancer: Pain Not Justified by the Gain

Katherine Van Loon and Alan P. Venook

1 ECOG 5202 was a randomized phase III study of oxaliplatin and 5-FU/leucovorin with or without bevacizumab for the treatment of patients who had undergone surgery for stage II colon cancer, stratified according to MSI status and 18q

Full access

New Issues in Systemic Therapy for Ovarian Cancer

Deborah K. Armstrong

may be just as effective.” Because median OS was about 30 months in each arm—significantly lower than seen in most GOG trials—the benefit of neoadjuvant chemotherapy is being further studied in randomized trials. Optimal Use of Bevacizumab in the

Full access

Induction of Prosurvival Molecules During Treatment: Rethinking Therapy Options for Photodynamic Therapy

Charles J. Gomer

improve results with PDT, hypothesized Dr. Gomer. He shared his results with bevacizumab (Avastin), a VEGF inhibitor, in combination with PDT in a Kapsoi sarcoma tumor model. 4 Gomer and Ferrario 4 found that combining PDT with bevacizumab resulted in a

Full access

NCCN News

NCCN Guidelines for Breast Cancer Updated; Bevacizumab Recommendation Affirmed The National Comprehensive Cancer Network (NCCN) recently updated the NCCN Clinical Practice Guidelines for Oncology (NCCN Guidelines) for Breast Cancer to affirm

Full access

Optimizing Systemic Therapy Selection in Metastatic Colorectal Cancer

Axel Grothey

. Patients should be tested for all RAS mutations to identify patients who will benefit from anti-EGFR agents. Chemotherapy plus either bevacizumab or EGFR antibodies are both viable options as first-line therapy in patients with RAS wild-type mutations

Full access

Proton Pump Inhibitors and Survival in Patients With Colorectal Cancer Receiving Fluoropyrimidine-Based Chemotherapy

Ganessan Kichenadasse, John O. Miners, Arduino A. Mangoni, Christos S. Karapetis, Ashley M. Hopkins, and Michael J. Sorich

leucovorin. Concomitant vascular endothelial growth factor receptor inhibitor (VEGFi) therapies administered were bevacizumab (BEV) or ramucirumab (RAM), depending on the trial. Concomitant PPIs used were esomeprazole, lansoprazole, omeprazole, pantoprazole

Full access

Ovarian Cancer, Version 2.2020, NCCN Clinical Practice Guidelines in Oncology

Deborah K. Armstrong, Ronald D. Alvarez, Jamie N. Bakkum-Gamez, Lisa Barroilhet, Kian Behbakht, Andrew Berchuck, Lee-may Chen, Mihaela Cristea, Maria DeRosa, Eric L. Eisenhauer, David M. Gershenson, Heidi J. Gray, Rachel Grisham, Ardeshir Hakam, Angela Jain, Amer Karam, Gottfried E. Konecny, Charles A. Leath III, Joyce Liu, Haider Mahdi, Lainie Martin, Daniela Matei, Michael McHale, Karen McLean, David S. Miller, David M. O’Malley, Sanja Percac-Lima, Elena Ratner, Steven W. Remmenga, Roberto Vargas, Theresa L. Werner, Emese Zsiros, Jennifer L. Burns, and Anita M. Engh

cancers: platinum-based intravenous chemotherapy, platinum-based IV/IP chemotherapy, and platinum-based IP chemotherapy plus bevacizumab, as outlined in Table 2 . Specific options and supporting data for each of these categories of treatment are described